Oncolytics Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Für Oncolytics Biotech wird ein Gewinn- und Umsatzwachstum von 47.6% bzw. 51.6% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 50.2% pro Jahr steigen soll.

Wichtige Informationen

47.6%

Wachstumsrate der Gewinne

50.23%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	25.2%
Wachstumsrate der Einnahmen	51.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	05 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Seeking Alpha • Apr 25

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

Summary Oncolytics is narrowing Pelareorep development toward anal cancer and metastatic colorectal cancer, making its bull case more concrete. Pelareorep may turn “cold” tumors “hot,” potentially improving chemotherapy and checkpoint inhibitor responses across GI cancers. CRC data showed an unusually high 33% ORR versus 6%-11% historical SoC. This is why it received the FDA’s Fast Track designation. SCAC data showed encouraging response rates and complete responses. ONCY scheduled discussions with the FDA for a single-arm registrational pathway. I reckon ONCY’s dilution and clinical trial risks remain significant. Yet, the upcoming ER updates could help reframe ONCY around clearer regulatory timelines. Read the full article on Seeking Alpha

Analyseartikel • Sep 03

Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Seeking Alpha • Mar 11

Oncolytics Biotech: Continuing To Justify The Negativity

Summary Oncolytics Biotech's main asset, pelareorep, shows mixed results in trials, with no definitive efficacy signals and ongoing financial struggles threatening operations. The GOBLET trial in pancreatic cancer continues, but key data readouts are not expected until late 2025, adding uncertainty. ONCY's financial situation is dire, with cash runway only into Q3 2025, raising serious concerns about their ability to fund operations. Given the high risk, low market cap, and lack of clear efficacy, I maintain a "Sell" rating and advise against investing in ONCY. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ONCY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2028	14	-26	N/A	N/A	3
12/31/2027	N/A	-30	N/A	N/A	4
12/31/2026	N/A	-30	N/A	N/A	5
3/31/2026	N/A	-33	-23	-23	N/A
12/31/2025	N/A	-29	-20	-20	N/A
9/30/2025	N/A	-25	-19	-19	N/A
6/30/2025	N/A	-22	-18	-18	N/A
3/31/2025	N/A	-22	-18	-18	N/A
12/31/2024	N/A	-23	-20	-20	N/A
9/30/2024	N/A	-20	-19	-19	N/A
6/30/2024	N/A	-20	-19	-19	N/A
3/31/2024	N/A	-21	-21	-21	N/A
12/31/2023	N/A	-21	-21	-21	N/A
9/30/2023	N/A	-24	-21	-21	N/A
6/30/2023	N/A	-20	-20	-20	N/A
3/31/2023	N/A	-18	-18	-18	N/A
12/31/2022	N/A	-18	-17	-17	N/A
9/30/2022	N/A	-17	-17	-17	N/A
6/30/2022	N/A	-19	-18	-18	N/A
3/31/2022	N/A	-21	-19	-18	N/A
12/31/2021	N/A	-21	-18	-18	N/A
9/30/2021	N/A	-22	-17	-17	N/A
6/30/2021	N/A	-24	-20	-20	N/A
3/31/2021	N/A	-23	-19	-19	N/A
12/31/2020	N/A	-18	-17	-17	N/A
9/30/2020	N/A	-24	-18	-18	N/A
6/30/2020	N/A	-22	-16	-16	N/A
3/31/2020	N/A	-20	-15	-15	N/A
12/31/2019	N/A	-26	N/A	-15	N/A
9/30/2019	N/A	-14	N/A	-13	N/A
6/30/2019	N/A	-14	N/A	-12	N/A
3/31/2019	N/A	-13	N/A	-8	N/A
12/31/2018	N/A	-12	N/A	-9	N/A
9/30/2018	N/A	-13	N/A	-8	N/A
6/30/2018	N/A	-13	N/A	-8	N/A
3/31/2018	N/A	-13	N/A	-12	N/A
12/31/2017	N/A	-12	N/A	-12	N/A
9/30/2017	N/A	-13	N/A	-12	N/A
6/30/2017	N/A	-13	N/A	-12	N/A
3/31/2017	N/A	-11	N/A	-10	N/A
12/31/2016	N/A	-11	N/A	-9	N/A
9/30/2016	N/A	-10	N/A	-10	N/A
6/30/2016	N/A	-10	N/A	-10	N/A
3/31/2016	N/A	-11	N/A	-12	N/A
12/31/2015	N/A	-10	N/A	-11	N/A
9/30/2015	N/A	-10	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ONCY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ONCY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ONCY wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ONCY wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ONCY wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ONCY in 3 Jahren voraussichtlich hoch sein wird

Wachstumsunternehmen entdecken

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/17 19:47
Aktienkurs zum Tagesende	2026/05/15 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Oncolytics Biotech Inc. wird von 19 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Douglas Loe	Cantor Fitzgerald Canada Corporation
Wang Chong	Edison Investment Research
Patrick Trucchio	H.C. Wainwright & Co.

Oncolytics Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2027

Forecast to breakeven in 2026

No longer forecast to breakeven

No longer forecast to breakeven

Recent updates

New minor risk - Market cap size

Oncolytics Biotech Reports 33% Response Rate With Pelareorep in Advanced Colorectal Cancer

Oncolytics Biotech Inc. Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

Oncolytics Biotech Inc Aligns with Fda on Planned Pivotal Anal Cancer Study

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths

Oncolytics Biotech Inc Schedules Type C FDA Meeting to Discuss Single-Arm Registrational Pathway for Pelareorep in Anal Cancer

New major risk - Shareholder dilution

New major risk - Financial position

No longer forecast to breakeven

New minor risk - Market cap size

Oncolytics Biotech Inc. Presents New Mechanistic And Translational Data Supporting Pelareorep as An Immune-Priming Backbone

Oncolytics Biotech Launches Randomized Colorectal Cancer Study

Oncolytics Biotech to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

Independent Director recently bought US$83k worth of stock

New minor risk - Market cap size

Oncolytics Biotech®? Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

New minor risk - Share price stability

Independent Director recently bought US$104k worth of stock

Oncolytics Biotech Inc. Appoints Yujun Wu as Vice President, Head of Biostatistics

Oncolytics Biotech Announces Updated Clinical Data from GOBlet Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Oncolytics Biotech®? Provides Update on Intellectual Property Strategy and Patent Filings

Oncolytics Biotech Inc. Expands Scientific Advisory Board with the Appointment of Eileen O’Reilly, Neil Segal, and Van Morris

Oncolytics Biotech Inc. Announces Promising Efficacy and Translational Data Supporting Pelareorep in Kras-Mutant Metastatic Colorectal Cancer

Oncolytics Biotech Inc. Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

New minor risk - Profitability

Oncolytics Biotech Inc. Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy

Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More than Double the Current Standard of Care

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech®? Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Is Oncolytics Biotech (NASDAQ:ONCY) In A Good Position To Deliver On Growth Plans?

New minor risk - Profitability

New major risk - Shareholder dilution

New major risk - Financial position

Oncolytics Biotech Inc. to Report Q2, 2025 Results on Aug 08, 2025

Oncolytics Biotech Inc. Begins Formal Discussions with the U.S. Food and Drug Administration Aimed at Finalizing A Pivotal Study Design

CEO & Director recently bought US$60k worth of stock

Oncolytics Biotech Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Oncolytics Biotech Inc. Appoints Andrew Aromando as Chief Business Officer

Oncolytics Biotech Inc. Appoints Jared Kelly as Chief Executive Officer

New minor risk - Share price stability

Oncolytics Biotech Inc., Annual General Meeting, Aug 08, 2025

New minor risk - Shareholder dilution

Oncolytics Biotech Inc. to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering.

No longer forecast to breakeven

Oncolytics Biotech: Continuing To Justify The Negativity

New minor risk - Profitability

New minor risk - Share price stability

Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Matt Coffey Steps Down as Chief Executive Officer of Oncolytics Biotech Inc

Forecast to breakeven in 2027

Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers At 2025 Asco GI Symposium

Oncolytics Biotech Inc. Announces Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data

Oncolytics Biotech Inc. Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial’s New Pancreatic Cancer Cohort

New major risk - Financial position

Oncolytics Biotech Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting

Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer

Oncolytics Biotech Inc., Annual General Meeting, May 15, 2024

New minor risk - Profitability

Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors

Forecast to breakeven in 2026

Oncolytics Biotech Inc. Announces the Anal Cancer Cohort of the Goblet Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

New minor risk - Share price stability

Oncolytics Biotech Inc. Presents Further Positive Pelareorep Translational Data At SITC

Oncolytics Biotech Inc. Announces Poster Presentation of Positive, Updated Results from the Phase 1/2 GOBLET Study

Oncolytics Biotech Inc. Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the Goblet Study

Oncolytics Biotech Inc. Unveils Results from Its Phase 2 Trial of A Drug for Metastatic Breast Cancer

Oncolytics Biotech Inc. has completed a Composite Units Offering in the amount of $15.00075 million.